- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05098704
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk (PSSIT)
Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study, platelet activation is targeted as it could play a key role in the pathogenesis of SSc. It has been shown in several publications that platelets are activated in SSc with a correlation between the level of activation and disease activity. Secondary to this activation, soluble and membrane effectors were increased, and induced vascular damages and fibrosis. The results obtained in the laboratory (CNRS UMR-5164) directly involved platelets in this mechanism by inducing the thymic stromal lymphopoietin (TSLP) production by endothelial cells and by showing the pro-fibrotic effect of TSLP. In vivo data in SSc murine model recently obtained, confirmed the preventive role on fibrosis of clopidogrel. The early control of this platelet activation could prevent the course of events leading to SSc.
The therapeutic strategy assessed in this study will be the oral administration of clopidogrel (75 mg per day) during two years to subjects presenting an association of specific dysimmunity and Raynaud phenomenon (RP). The administration of clopidogrel will be double-blinded versus placebo.
Subjects will be included and treated during a 2-year period and will be followed for a period of 36 months after treatment, i.e. a total of 60 months. The follow-up will be every six months mainly comprising clinical examination, patient reported outcomes and blood sampling.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Thomas BARNETCHE, PhD
- Email: thomas.barnetche@chu-bordeaux.fr
Study Contact Backup
- Name: Marie-Elise TRUCHETET, Prof
- Phone Number: +33 05.56.79.55.56
- Email: marie-elise.truchetet@chu-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France
- Recruiting
- CHU de Bordeaux - service de rhumatologie
-
Contact:
- Thomas BARNETCHE, PhD
- Email: thomas.barnetche@chu-bordeaux.fr
-
Contact:
- Marie-Elise TRUCHETET, Prof
- Email: marie-elise.truchetet@chu-bordeaux.fr
-
Principal Investigator:
- Marie-Elise TRUCHETET, Prof
-
Sub-Investigator:
- Joel CONSTANS, Prof
-
Sub-Investigator:
- Estibaliz LAZARO, Prof
-
Sub-Investigator:
- Julien SENESCHAL, Prof
-
Sub-Investigator:
- Pierre DUFFAU, Prof
-
Brest, France
- Recruiting
- CHU de Brest - Service de rhumatologie
-
Contact:
- Alain SARAUX, Prof
- Email: alain.saraux@chu-brest.fr
-
Principal Investigator:
- Alain SARAUX, Prof
-
Libourne, France
- Not yet recruiting
- CH de Libourne - service de rhumatologie
-
Contact:
- Jean-Philippe VERNHES, MD
- Email: philippe.vernhes@ch-libourne.fr
-
Principal Investigator:
- Jean-Philippe VERNHES, MD
-
Mont-de-Marsan, France
- Recruiting
- CH de Mont-de-Marsan - service de rhumatologie
-
Contact:
- Marion MIRABEL, MD
- Email: marion.mirabel@ch-mdm.fr
-
Principal Investigator:
- Marion MIRABEL, MD
-
Montpellier, France
- Not yet recruiting
- CHU de Montpellier - service de médecine vasculaire
-
Contact:
- Pierrick HENNETON, MD
- Email: p-henneton@chu-montpellier.fr
-
Principal Investigator:
- Pierrick HENNETON, MD
-
Paris, France
- Recruiting
- AP-HP - Hôpital Cochin - service de médecine interne
-
Contact:
- Benjamin CHAIGNE, MD
- Email: benjamin.chaigne@aphp.fr
-
Principal Investigator:
- Benjamin CHAIGNE, MD
-
Pau, France
- Not yet recruiting
- CH de Pau - service de médecine interne
-
Contact:
- Xavier DELBREL, MD
- Email: xavier.delbrel@ch-pau.fr
-
Principal Investigator:
- Xavier DELBREL, MD
-
Toulouse, France
- Not yet recruiting
- CHU de Toulouse - service de médecine interne
-
Contact:
- Grégory PUGNET, MD
- Email: pugnet.g@chu-toulouse.fr
-
Principal Investigator:
- Gregory Pugnet, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient over 18 years old, and less than 85 years old.
- Patient with positive AAN (AAN ≥ 1/160) with the following specificity: anti-Scl70 or anti-centromere or anti-RNApolIII, or any other auto-antibodies related to systemic sclerosis
- Patient with RP reported by the subject and confirmed by the physician.
- Patient affiliated to a health insurance system.
- Patient who accepts to participate to the study and signs an inform consent form.
Exclusion Criteria:
- Patient with an SSc diagnosis according to ACR/EULAR 2013 criteria.
- Patient with skin fibrosis at screening.
- Patient with antiplatelet treatment at screening.
- Patient with contraindications to clopidogrel.
- Patient treated by immunosuppressive agent at screening.
- Patient treated by anticoagulants at screening
- Pregnant or breastfeeding women.
- Women of childbearing age refusing effective contraception method during the study treatment (24 months).
- Incompetent adults (i.e. Individuals under the protection of a conservator)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
75 mg daily during 24 months
|
Experimental: clopidogrel
|
75 mg daily during 24 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of occurrence of SSc at 5 years according to American College of Rheumatology (ACR) / European League Against Rhumatism (EULAR) 2013 criteria in the two randomization groups
Time Frame: 60 months after baseline (Day 0)
|
60 months after baseline (Day 0)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of occurrence of cutaneous fibrosis (sclerodactyly or other affected area) clinically assessed by at least 2 independent investigators in the two randomization groups
Time Frame: 60 months after baseline (Day 0)
|
60 months after baseline (Day 0)
|
Mean of modified Rodnan skin score (which varies between 0 and 51, with higher values mean higher disease severity) in the two randomization groups.
Time Frame: 60 months after baseline (Day 0)
|
60 months after baseline (Day 0)
|
Mean of Cochin hand function scale (which varies between 0 and 90, with higher values mean higher disease severity) in the two randomization groups.
Time Frame: 60 months after baseline (Day 0)
|
60 months after baseline (Day 0)
|
Proportion of sex ratio at inclusion in the two randomization groups.
Time Frame: At baseline (Day 0)
|
At baseline (Day 0)
|
Mean age at inclusion in the two randomization groups.
Time Frame: At baseline (Day 0)
|
At baseline (Day 0)
|
Proportion of patients exposed to toxic products at inclusion in the two randomization groups.
Time Frame: At baseline (Day 0)
|
At baseline (Day 0)
|
Proportion of patients exposed to toxic products at 5 years in the two randomization groups.
Time Frame: 60 months after baseline (Day 0)
|
60 months after baseline (Day 0)
|
Proportion of patients affected by a limited form of SSc at 5 years in the two randomization groups.
Time Frame: 60 months after baseline (Day 0)
|
60 months after baseline (Day 0)
|
Proportion of patients affected by a diffuse form of SSc at 5 years in the two randomization groups.
Time Frame: 60 months after baseline (Day 0)
|
60 months after baseline (Day 0)
|
Proportion of patients presenting a specific antibody positivity (anti-scl70, anti-centromere) in the two randomization groups at inclusion.
Time Frame: At baseline (Day 0)
|
At baseline (Day 0)
|
Proportion of patients presenting megacapillaries by capillaroscopy at 5 years in the two randomization groups.
Time Frame: 60 months after baseline (Day 0)
|
60 months after baseline (Day 0)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marie-Elise TRUCHETET, Prof, CHU Bordeaux
- Study Chair: Linda WITTKOP, MD, University of Bordeaux
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Skin Diseases
- Connective Tissue Diseases
- Sclerosis
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Clopidogrel
Other Study ID Numbers
- CHUBX 2017/45
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
Horizon Pharma Ireland, Ltd., Dublin IrelandEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
Horizon Therapeutics Ireland DACRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
W. Leroy GriffingRecruitingSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
-
Mitsubishi Tanabe Pharma America Inc.CompletedDiffuse Cutaneous Systemic SclerosisSpain, Belgium, United States, United Kingdom, Poland, Canada, Germany, Italy
Clinical Trials on clopidogrel treatment
-
Ruhr University of BochumCompletedCoronary Artery DiseaseGermany
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedSystemic Lupus ErythematousFrance
-
Korea University Anam HospitalCompleted
-
Chinese PLA General HospitalUnknownCLOPIDOGREL, POOR METABOLISM of (Disorder)China
-
Ospedale San DonatoCompletedAcute Myocardial InfarctionItaly
-
Seoul National University HospitalHanyang University; Kangbuk Samsung Hospital; Keimyung University Dongsan Medical... and other collaboratorsRecruitingCoronary Artery DiseaseKorea, Republic of
-
University Hospital Inselspital, BerneUniversity Hospital, Geneva; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsUnknownStroke | Transient Ischemic AttackUnited States, Switzerland, Germany, Belgium, Italy, Spain
-
St. Josef Hospital BochumCompletedVascular Surgery Patient With PAD / Carotid StenosisGermany
-
University of PecsTerminatedStable Angina Pectoris | Ad Hoc Percutaneous Coronary InterventionHungary
-
Hospital Central San Luis Potosi, MexicoUnknownAcute Coronary Syndrome